Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,516,008
  • Shares Outstanding, K 705,260
  • Annual Sales, $ 15,281 M
  • Annual Income, $ 4,046 M
  • 60-Month Beta 1.57
  • Price/Sales 4.49
  • Price/Cash Flow 10.97
  • Price/Book 8.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 2.45
  • Number of Estimates 2
  • High Estimate 2.56
  • Low Estimate 2.34
  • Prior Year 1.86
  • Growth Rate Est. (year over year) +31.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.26 +3.88%
on 05/29/19
97.89 -1.03%
on 06/18/19
+1.46 (+1.53%)
since 05/17/19
3-Month
86.21 +12.38%
on 03/28/19
97.89 -1.03%
on 06/18/19
+7.81 (+8.77%)
since 03/19/19
52-Week
58.59 +65.35%
on 12/26/18
97.89 -1.03%
on 06/18/19
+17.44 (+21.95%)
since 06/19/18

Most Recent Stories

More News
Big Drugmakers That May Tread the M&A Path After Pfizer

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

CELG : 97.21 (+0.06%)
ARRY : 46.70 (+0.26%)
JNJ : 140.52 (+0.21%)
GILD : 68.21 (+0.01%)
AMGN : 181.89 (+0.15%)
PFE : 43.38 (+0.72%)
BMY : 48.06 (+0.56%)
Big Drugmakers That May Tread the M&A Path After Pfizer

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

CELG : 97.21 (+0.06%)
ARRY : 46.70 (+0.26%)
JNJ : 140.52 (+0.21%)
GILD : 68.21 (+0.01%)
AMGN : 181.89 (+0.15%)
PFE : 43.38 (+0.72%)
BMY : 48.06 (+0.56%)
Celgene (CELG) Hits 52-Week High, Can the Run Continue?

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CELG : 97.21 (+0.06%)
INVA : 14.48 (+0.98%)
MITO : 12.81 (+0.08%)
NLNK : 1.58 (-0.63%)
5 Solid Stocks Near 52-Week High Promise to Touch Peak Point

Investors target stocks that are on a bullish run of late. Stocks witnessing price strength show a high chance of carrying the winning momentum forward.

TGT : 86.18 (-0.34%)
CELG : 97.21 (+0.06%)
ARNC : 23.59 (+0.25%)
DOX : 62.06 (+0.57%)
TSN : 76.49 (-0.89%)
Celgene (CELG) Gains But Lags Market: What You Should Know

Celgene (CELG) closed the most recent trading day at $96.04, moving +0.89% from the previous trading session.

CELG : 97.21 (+0.06%)
Celgene's Filing for Ozanimod Accepted for Review in US/EU

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

CELG : 97.21 (+0.06%)
NVS : 91.17 (-0.14%)
TEVA : 8.32 (-0.48%)
BIIB : 233.51 (+0.21%)
Novartis Appoints New Pharma Unit Head, Gives Other Updates

Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

CELG : 97.21 (+0.06%)
NVS : 91.17 (-0.14%)
BMY : 48.06 (+0.56%)
SNY : 43.31 (+0.46%)
Celgene & Acceleron's BLA for Luspatercept Accepted by FDA

Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.

CELG : 97.21 (+0.06%)
JNJ : 140.52 (+0.21%)
XLRN : 40.62 (-0.17%)
BMY : 48.06 (+0.56%)
Mallinckrodt Down After Agreement with DOJ for Litigation

Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.

CELG : 97.21 (+0.06%)
MNK : 9.49 (+1.50%)
RHHBY : 34.8700 (+0.09%)
BMY : 48.06 (+0.56%)
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people...

CELG : 97.21 (+0.06%)
CELGZ : 0.66 (-7.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CELG with:

Business Summary

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID,...

See More

Key Turning Points

2nd Resistance Point 98.24
1st Resistance Point 97.69
Last Price 97.21
1st Support Level 96.80
2nd Support Level 96.46

See More

52-Week High 97.89
Last Price 97.21
Fibonacci 61.8% 82.88
Fibonacci 50% 78.24
Fibonacci 38.2% 73.60
52-Week Low 58.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar